2.4. Outcomes and measurements
ADVERSE EVENTS, SECONDARY
The primary efficacy marker was the change in MPOD after 6 months of administration relative to that at baseline. To improve data accuracy, the MPOD was evaluated at least 3 times. The secondary efficacy markers were change in VA, change in CS, and change in electroretinogram (ERG) measurements (all relative to baseline values). The safety marker was the presence or absence of adverse events.